Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.18B 16.04B 14.72B 27.68B 1,914B 28.13B 189B 74.12B 960B 75.19B 73.56B 3,174B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.53B 17.3B 15.87B 29.84B 2,064B 30.34B 204B 79.93B 1,035B 81.09B 79.32B 3,423B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+1.50%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 44.9
Extreme 44.9
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
108.99
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap.
3/23/26 Free

Head of Human Resources

329,891 0.1728%
3/23/26 Issuer sale

General Counsel

93,932 0.0492%
2/27/26 Fiscal year

Chief Executive Officer

168,201 0.0882%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+132.67%+25.84% 20.03B
+4.42%+1.19%+103.42%+296.74% 3.92B
+3.79%-5.62%+42.61%+63.13% 3.27B
+13.44%+16.69%+202.50%+25.04% 3.18B
+1.36%-1.29%+303.63%+441.76% 2.39B
-3.86%-8.89%-28.23%-30.41% 2.23B
+18.17%-3.67%+9.37% - 1.52B
-0.99%-7.83%+6.76%+43.54% 977M
+24.83%+24.74%+187.25%-31.20% 855M
-2.29%-5.21%-36.61%-5.08% 555M
Average +5.96%-3.21%+92.34%+92.15% 3.89B
Weighted average by Cap. +3.38%-1.68%+119.97%+79.34%

Financials

2024 2025
Net sales 2.76B 2.37B 2.21B 2.03B 3.81B 264B 3.88B 26.08B 10.21B 132B 10.36B 10.13B 437B 3.25B 2.79B 2.6B 2.39B 4.49B 310B 4.56B 30.69B 12.02B 156B 12.19B 11.93B 515B
Net income -1.03B -883M -824M -756M -1.42B -98.34B -1.45B -9.72B -3.81B -49.32B -3.86B -3.78B -163B -208M -178M -167M -153M -287M -19.88B -292M -1.97B -770M -9.97B -781M -764M -32.96B
Net Debt 1.74B 1.49B 1.39B 1.28B 2.4B 166B 2.44B 16.42B 6.43B 83.3B 6.52B 6.38B 275B 1.57B 1.35B 1.26B 1.15B 2.17B 150B 2.21B 14.84B 5.81B 75.27B 5.9B 5.77B 249B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock